Radiotekhnika Publishing House

2025

Vegf signaling pathway components and matrix metalloproteinases - in tumors of patients with ovarian neoplasms Вопросы биологической, медицинской и фармацевтической химии, No. 8, 2014 pp. 47-52
Clinical significance of vegf and upa evaluation in breast cancer Вопросы биологической, медицинской и фармацевтической химии, No. 8, 2014 pp. 38-45

Ovarian cancer and matrix metalloproteinases Technologies of Living Systems, No. 4, 2013 pp. 3-18

Angiogenic factors in ovarian cancer Technologies of Living Systems, No. 9, 2012 pp. 3-14
Sensitivity of Breast Cancer Cells Cultured in Vitro to Hypoxia: the Role of Estrogen Receptors Machinery Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 60-63
Comparative Analysis of Matrix Metalloproteinase-2 in Blood Serum and Tumors 64 of Patients with Malignant, Borderline and Benign Ovarian Neoplasms Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 36-40
Vascular Endothelial Growth Factor and its Type 1 and 2 Receptors in Ovarian Tumor Patients - Serum Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 30-35

Matrix Metalloproteinases in Ovarian Cancer Patients Technologies of Living Systems, No. 7, 2011 pp. 50-58матриксная мета
Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors (TIMPs), Role in the Breast Cancer Development Вопросы биологической, медицинской и фармацевтической химии, No. 12, 2011 pp. 37-46
Clinical Prospects of Matrix Metalloproteinases and Their Tissue Inhibitors Study in Ovarian Cancer Patients Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2011 pp. 27-36
IGF System and Breast Cancer Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2011 pp. 13-20